|
|
|
|
|
16.03.26 - 12:36
|
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized (Business Wire)
|
|
|
Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized
CRC leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month median overall survival in heavily pretreated microsatellite stable (MSS) metastatic CRC (mCRC) patients
BATTMAN Phase 3 registrational trial underway: First global next-generation CTLA-4/PD-1 combination registrational trial in refractory MSS mCRC
France expands reimbursed AAC access: Metastatic ovarian cancer and sarcoma added alongside MSS mCRC
Zydus collaboration strengthens balance sheet and manufacturing capacity: Strategic capital and dedicated U.S. biologics production secured to support BOT+BAL development for commercialization
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) immunotherapy program ...
|
|
|
|
|
|
|
10.03.26 - 12:33
|
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs (Business Wire)
|
|
|
Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programsLEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.
The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform the initiation of its commercial supply of Agenus' lead programs. They also include additional manufacturing work to satisfy regulatory requirements for BLA and MAA readiness, to build upon existing inventory in anticipation of increasing demand across clinical development programs, authorized early access pathways, and to support potential g...
|
|
|
04.03.26 - 22:36
|
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #Agenus--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.
Agenus will host a stakeholder briefing webcast in late March to spotlight key strategic plans, data milestones and provide an update on the global botensilimab (BOT) and balstilimab (BAL) development program.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, an...
|
|
|
|
|
16.01.26 - 11:36
|
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal (PBR)
|
|
|
The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus
The post Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
18.11.25 - 14:42
|
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France′s AAC (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program.
BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has historically derived limited benefit from immunotherapy despite substantial unmet medical need.
Dr. Iglesias brings over 30 years of global oncology and immuno-oncology drug development experience. Previously, at Abraxis BioScience and Celgene, he led late-stage develop...
|
|
|
|
|
|
|
10.11.25 - 13:36
|
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances (Business Wire)
|
|
|
France grants reimbursed access with patients having commenced treatment
Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients
Phase 3 on track to commence in fourth quarter 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial.
Access & Regulatory
France authorizes reimbursed AAC for BOT/BAL. In September, France's medicines agency (ANSM) authorized reimbursed compassionate access (Accès Compassionnel, AAC) for BOT/BAL in refractory MSS mCRC without active liver metastases—the first government-funded access for this population ...
|
|
|
|
|
|
|
05.11.25 - 19:48
|
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025.
The company also plans to host a stakeholder briefing webcast in late November to provide a corporate and clinical development update. Additional details regarding the webcast will be announced in the coming weeks.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
